EMA and FDA Accept UCB’s Marketing Applications for Bimekizumab

News
Article

FDA and EMA have accepted the biologics license application and marketing authorization application, respectively, for bimekizumab.

Global biopharmaceutical company, UCB, has announced that the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) have accepted the biologics license application (BLA) and marketing authorization application (MAA), respectively, for bimekizumab.

In a Sept. 22, 2020 press release, the company revealed that the application submissions have been accepted for the investigational humanized monoclonal IgG1 antibody, bimekizumab, to be used as a treatment for adults with moderate to severe plaque psoriasis. The applications were based on data from a global Phase III clinical development program.

“After a series of positive Phase III data readouts, we are delighted to announce that the US FDA and EMA have accepted our applications to file bimekizumab as a potential new treatment for psoriasis,” said Emmanuel Caeymaex, executive vice-president Immunology Solutions and head of US, UCB, in the press release. “This milestone brings us one step closer to being able to offer a meaningful new treatment option for people living with this debilitating disease. UCB is committed to providing innovative solutions for people living with serious inflammatory diseases like psoriasis.”

Evaluation of the safety and efficacy of bimekizumab are still ongoing and the drug is not yet approved by any regulatory authority worldwide. The drug is also under evaluation for potential indications in psoriatic arthritis.

Source: UCB

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes